Mutation of the gene encoding the circadian clock component PERIOD2 in oncogenic cells confers chemoresistance by up-regulating the Aldh3a1 gene

• Published in: The Journal of biological chemistry 2019-01, Vol.294 (2), p.547-558
• Main Authors: Katamune, Chiharu, Koyanagi, Satoru, Hashikawa, Ken-ichi, Kusunose, Naoki, Akamine, Takahiro, Matsunaga, Naoya, Ohdo, Shigehiro
• Format: Article
• Language: English
• Subjects: aldehyde dehydrogenase; Aldehyde Dehydrogenase - genetics; Aldh3a1; Animals; anticancer drug; cancer; Carcinogenesis - drug effects; Carcinogenesis - genetics; Cell Biology; Cells, Cultured; chemoresistance; chemotherapy; chromatin modification; Circadian Clocks; circadian rhythm; clock gene; Drug Resistance, Neoplasm; Mice, Inbred ICR; Mutation; Neoplasms - drug therapy; Neoplasms - etiology; Neoplasms - genetics; oncogene; Period Circadian Proteins - genetics; Period2; reactive oxygen species (ROS); Up-Regulation
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.RA118.004942

Disruption of circadian rhythms has been implicated in an increased risk for cancer development. The Period2 (Per2) gene encodes one of the major components of the mammalian circadian clock, which plays a key role in controlling the circadian rhythms in physiology and behavior. PER2 has also been reported to suppress the malignant transformation of cells, but its role in the regulation of cancer susceptibility to chemotherapeutic drugs remains unclear. In this study, we found that oncogene-transformed embryonic fibroblasts prepared from Per2-mutant (Per2m/m) mice, which are susceptible to both spontaneous and radiation-induced tumorigenesis, were resistant against common chemotherapeutic drugs and that this resistance is associated with up-regulation of the aldehyde dehydrogenase 3a1 (Aldh3a1) gene. Co-expression of the oncogenes H-rasV12 and SV40 large T-antigen induced malignant transformation of both WT and Per2m/m cells, but the cytotoxic effects of the chemotherapeutic agents methotrexate, gemcitabine, etoposide, vincristine, and oxaliplatin were significantly alleviated in the oncogene-transformed Per2m/m cells. Although introduction of the two oncogenes increased the expression of Aldh3a1 in both WT and Per2m/m cells, the ALDH3A1 protein levels in the Per2m/m cells were ∼7-fold higher than in WT cells. The elevated ALDH3A1 levels in the oncogene-transformed Per2m/m cells were sufficient to prevent chemotherapeutic drug–induced accumulation of reactive oxygen species. Consequently, shRNA-mediated suppression of Aldh3a1 expression relieved the chemoresistance of the Per2m/m cells. These results suggest a role for mutated PER2 in the development of multiple drug resistance and may inform therapeutic strategies for cancer management.